Why Tigecycline Resistance Threatens Antibiotic Stewardship
Tigecycline, a glycylcycline antibiotic, treats multidrug-resistant infections like those from Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae. Resistance undermines stewardship programs, which aim to preserve antibiotic effectiveness by promoting judicious use. Emerging resistance reduces tigecycline's utility as a last-resort option, forcing reliance on fewer drugs and accelerating broader resistance [1].
How Tigecycline Resistance Develops
Resistance arises mainly through efflux pumps (e.g., Tet(X) enzymes that export the drug) and ribosomal protection proteins. Clinical isolates show MICs rising from ≤2 mg/L (susceptible) to >8 mg/L, often in ICU patients with prolonged exposure. Mobile genetic elements spread these mechanisms across species like E. coli and Klebsiella, turning tigecycline into a resistance driver [2][3].
Impact on Treatment of Critical Infections
In ventilator-associated pneumonia or complicated intra-abdominal infections, tigecycline failure rates climb with resistant strains, linked to 20-30% higher mortality. Stewardship programs track rising MIC90 values in surveillance data, signaling the need to restrict use earlier to delay resistance spread [4].
Role in Broader Resistance Ecosystems
Tigecycline's broad spectrum selects for cross-resistant pathogens, including those evading colistin or new beta-lactamase inhibitors. Programs monitor this via tools like WHONET, as tigecycline overuse in high-burden settings (e.g., Asia-Pacific) correlates with pan-resistant outbreaks [5].
Stewardship Strategies to Counter Resistance
Guidelines recommend tigecycline only for confirmed susceptible MDR infections, with de-escalation to narrower agents. Programs enforce prior authorization, therapeutic monitoring, and combination therapy (e.g., with meropenem) to lower failure risk. Resistance tracking via EUCAST breakpoints guides local restrictions [1][6].
Evidence from Surveillance and Outbreaks
Global networks like SENTRY report tigecycline resistance in 5-15% of Enterobacterales, doubling in some regions since 2010. Outbreaks in China and India highlight stewardship gaps, with genomic studies confirming clonal spread of resistant Acinetobacter [2][7].
Sources
[1]: IDSA Guidance on MDR Gram-Negatives
[2]: Clinical Microbiology Reviews on Tigecycline Resistance
[3]: Antimicrobial Agents and Chemotherapy - Tet(X) Mechanisms
[4]: Lancet Infectious Diseases - Tigecycline Outcomes
[5]: WHO GLASS Report 2022
[6]: EUCAST Tigecycline Breakpoints
[7]: SENTRY Antimicrobial Surveillance